TGRX-326
- Generic Name
- TGRX-326
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 3
Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 321
- Registration Number
- NCT06082635
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT05955391
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT05441956
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath